ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/biliary/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Biliary - Advanced/metastatic
11
trial(s) found.
NCT07710885
Advanced
Phase 3
Recruiting
A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers (
FOENIX-BTC
)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
antimetabolite
pan-FGFR inhibitor,irreversible
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT07221253
Advanced
Phase 3
Recruiting
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02) (
AB02
)
anti-PD-L1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Biliary tract cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06760819
Advanced
Phase 2
Recruiting
A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (
panSOHO
)
EGFR/ERBB2 inhibitor,mutant-selective,non-covalent
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Endometrial cancer
NOT Biliary tract cancer
NOT Colorectal cancer
NOT Non-small cell lung cancer
NOT Urothelial carcinoma
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
QLD
4215 - Southport - ICON Cancer Care
NCT06501625
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants With Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation (
S095031-210
)
IDH1 R132 inhibitor
anti-PD-L1 monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Cholangiocarcinoma
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06467357
Advanced
Phase 3
Recruiting
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (
DESTINY-BTC01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-PD-L1 monoclonal antibody
antimetabolite
bispecific PD-1/TIGIT antibody
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06441747
Advanced
Phase 2
Recruiting
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (
BIL-PPP
)
PARP1/2 inhibitor
anti-PD-L1 monoclonal antibody
Cholangiocarcinoma
Gallbladder cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2541 - Nowra - Shoalhaven District Memorial Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
Biliary tract cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05727176
Advanced
Phase 2
Recruiting
Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements (
FOENIX-CCA4
)
pan-FGFR inhibitor,irreversible
Cholangiocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05636215
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors (
CIBI354A101
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Biliary tract cancer
Breast cancer
Colorectal cancer
Gastric cancer
Gynaecological cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (11)
Completed (1)
Recruitment Country and State
NSW (10)
VIC (9)
QLD (6)
WA (6)
SA (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (3)
Phase 2 (4)
Phase 3 (3)
Trial Type
Advanced (11)
Cancer Therapy Class
PD-1/PD-L1
55%
PD-L1
45%
PD-1
36%
ERBB2
27%
FGFR
18%
FGFR1
18%
FGFR1/2/3
18%
FGFR2
18%
FGFR3
18%
FGFR4
18%
TIGIT
18%
EGFR
9%
IDH1
9%
IDH1 R132
9%
PARP
9%
Trop2
9%
CLDN18.2
9%
MET
9%
SMO
9%
VEGF
9%
Facility
3168 - Clayton - Monash Medical Centre (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (3)
2031 - Randwick - Scientia Clinical Research Ltd (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
6000 - Perth - Royal Perth Hospital (1)
NA
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2109 - North Ryde - Macquarie University Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
4215 - Southport - ICON Cancer Care (1)
2139 - Concord - Concord Repatriation General Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2541 - Nowra - Shoalhaven District Memorial Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3002 - East Melbourne - Epworth Freemasons (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
6009 - Nedlands - One Clinical Research (1)
2031 - Randwick - Prince of Wales Hospital (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
Cancer Type
Cancer
Gastrointestinal cancer
Solid tumour
Biliary tract cancer
Hepatobiliary cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Breast cancer
Colorectal cancer
Gynaecological cancer
Lower gastrointestinal cancer
Cholangiocarcinoma
Gastroesophageal cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Pancreatic cancer
Gastric cancer
Oesophageal cancer
Thoracic cancer
Cervical cancer
Colorectal adenocarcinoma
Endometrial cancer
HPV-related cancer
HPV16-positive cancer
Urogenital cancer
Urothelial carcinoma
Viral-related cancer
Gallbladder cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Breast adenocarcinoma
Epithelial Ovarian Cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Ovarian cancer
Triple-negative breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy